Orchid Pharma Limited — Updates, 12-02-2025: Press Release

Orchid Pharma Limited reported a robust 26% year-on-year growth in Profit After Tax (PAT) for the first nine months of FY 2024-25, driven primarily by advancements in its Anti-Microbial Stewardship (AMS) division. This division is fundamental to the company’s long-term strategy and is expected to enhance scalability in combating antimicrobial resistance. MD Manish Dhanuka highlighted the company’s commitment to innovation and operational excellence, noting the progress of the AMS division and the potential of its product pipeline, including the novel drug Enmetazobactam and ORBLICEF, developed in collaboration with Cipla. Orchid's strategic R&D initiatives position it well for sustained growth. The company emphasizes addressing global healthcare challenges while maintaining a focus on sustainable development and expanding its market reach, indicating a positive outlook for the future.